UCB, IBM complete initial phase of super-computer project in improving epilepsy care

19 May 2013 (Last Updated May 19th, 2013 18:30)

Global biopharmaceutical firm UCB and technology major IBM have announced that the initial phase of their joint project, designed to exploit super-computer power in the search for better care for epilepsy patients, has been completed.

Global biopharmaceutical firm UCB and technology major IBM have announced that the initial phase of their joint project, designed to exploit super-computer power in the search for better care for epilepsy patients, has been completed.

The project will leverage big data and analytics of IBM to address the urgent public health issue and deliver personalised care for people with epilepsy.

"We have partnered with IBM to explore this concept of streamlining large amounts of data into actionable approaches to epilepsy care."

UCB chief medical officer, and global projects and development executive vice-president Dr. Iris Löw-Friedrich said the company recognises the need to collaborate with a diverse group of internal and external experts in order to deliver best-in-class solutions to patients.

"We have partnered with IBM to explore this concept of streamlining large amounts of data into actionable approaches to epilepsy care," Löw-Friedrich added.

The power of cognitive computing capabilities, such as IBM's Watson, will be exploited for patient care as part of the project.

Both companies are jointly working to create the comprehensive bank of scientific literature and patient data on epilepsy, which will enable healthcare professionals across the globe to access the latest information that aids in improved patient care.

The completion will now allow healthcare providers to combine own clinical patient assessment with the system's predictive analytics to find the success rates of specific approaches to care.

UCB has adopted an open innovation model wherein both internal and external experts would collaborate to address unmet needs for people living with severe diseases of the immune system and the central nervous system.